Deciphera Pharmaceuticals Inc $ 43.78 1.19 (2.79%)
Volume:
332,818
Avg Vol (1m):
463,781
Market Cap $:
2.52 Bil
Enterprise Value $:
2.00 Bil
PE Ratio:
0.00
PB Ratio:
4.61
Financial Strength | 6/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 17.68 | ||
Equity-to-Asset | 0.85 | ||
Debt-to-Equity | 0.06 | ||
Debt-to-EBITDA | -0.12 | ||
Piotroski F-Score | 2 | ||
Altman Z-Score | 13.34 | ||
Beneish M-Score | 0.64 | ||
WACC vs ROIC |
Profitability Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -644.36 | ||
Net Margin % | -633.19 | ||
ROE % | -45.15 | ||
ROA % | -39.85 | ||
ROC (Joel Greenblatt) % | -750.69 | ||
3-Year EBITDA Growth Rate | -16.7 | ||
3-Year EPS without NRI Growth Rate | -16.9 |
DCPH
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 4.61 | ||
PS Ratio | 59 | ||
EV-to-EBIT | -7.51 | ||
EV-to-EBITDA | -7.58 | ||
EV-to-Revenue | 47.57 | ||
Current Ratio | 8.34 | ||
Quick Ratio | 8.26 | ||
Days Inventory | 6327.21 | ||
Days Sales Outstanding | 120.51 | ||
Days Payable | 19966.31 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -19.6 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 4.61 | ||
Earnings Yield (Greenblatt) % | -13.32 |